卡培他滨维持治疗晚期胃癌临床疗效分析

Clinical analysis of capecitabine maintenance treatment in patients with advanced gastric cancer

目的分析晚期胃癌患者一线治疗后使用卡培他滨维持治疗的临床疗效。方法分析该院2014-02~2016-02一线化疗后(奥沙利铂130 mg/m^2,d1+卡培他滨1000 mg/m^2bid,d1~14,21 d为一个周期)病情稳定的晚期胃癌患者64例。按照患者意愿分为卡培他滨维持治疗组和对照组各32例,维持治疗组给予卡培他滨1000 mg/m^2bid,d1~14,21 d为一个周期;对照组仅给予对症支持。通过Kaplan-Meier法对两组患者的疾病进展时间(TTP)及总生存时间(OS)进行差异性检验。并分析卡培他滨维持治疗的不良反应。结果维持治疗组与对照组的中位TTP分别为7.6个月和6.0个月(P<0.05),中位OS分别为11.9个月和9.5个月(P<0.05)。卡培他滨不良反应主要为1~2度的恶心呕吐、手足综合征等。结论卡培他滨单药维持治疗可延长胃癌患者TTP及OS,且毒副作用小。

Objective To analyse the clinical effects of capecitabine maintenance therapy after first-line treatment on patients with advanced gastric cancer.Methods Sixty-four stable advanced gastric cancer patients from February 2014 to February 2016 were retrospectively analyzed after a first-line chemotherapy(oxaliplatin 130 mg/m^2,d1+capecitabine 1000 mg/m^2 bid,d1~14,21 days as a cycle).According to the patients’wishes,the patients were divided into the capecitabine maintenance treatment group(n=32,capecitabine 1000 mg/m^2 bid,d1~14,21 days as a cycle)and the control group(n=32,symptomatic support only).The differences in time to progression(TTP)and overall survival(OS)time between the two groups were tested by Kaplan-Meier method.The adverse reactions of capecitabine maintenance therapy were analyzed.Results The median TTP was 7.6 months in the capecitabine maintenance treatment group and 6.0 months in the control group,with a significant difference between the two groups(P<0.05).The median OS was 11.9 months in the capecitabine maintenance treatment group and 9.5 months in the control group,with a significant difference between the two groups(P<0.05).The main adverse reactions of capecitabine were nausea and vomiting of 1~2 degrees,hand-foot syndrome,etc.Conclusion Capecitabine monotherapy can prolong TTP and OS in patients with gastric cancer,with less toxic and side effects.